Insight Molecular Diagnostics Inc. announced the online publication in the American Journal of Transplantation of new data demonstrating the statistical superiority of its flagship GraftAssure transplant rejection monitoring assay. The study showed that the novel GraftAssure Combination Model score, which integrates relative and absolute DNA fragment measurements, strongly correlates with kidney transplant rejection, confirming its reliability over non-rejection cases. First presented at the World Transplant Congress in 2025, the findings highlight the assay's potential to help physicians distinguish rejection from other causes of organ damage. The data and its implications will be further discussed at the American Transplant Congress in Boston from June 20 to 24, 2026. Meanwhile, BTIG reiterated its Neutral rating on May 15, awaiting FDA approval of GraftAssureDx, the company's test kit designed to expand access to kidney transplant monitoring in a market exceeding two billion dollars.
Insight Molecular Diagnostics Inc.New data shows statistical superiority of GraftAssure assay in kidney transplant rejection monitoring.